370 related articles for article (PubMed ID: 23524525)
41. The ratio of leptin to adiponectin can be used as an index of insulin resistance.
Oda N; Imamura S; Fujita T; Uchida Y; Inagaki K; Kakizawa H; Hayakawa N; Suzuki A; Takeda J; Horikawa Y; Itoh M
Metabolism; 2008 Feb; 57(2):268-73. PubMed ID: 18191059
[TBL] [Abstract][Full Text] [Related]
42. Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes.
Hermann LS; Ranstam J; Vaaler S; Melander A
Diabetes Obes Metab; 1999 Jul; 1(4):227-32. PubMed ID: 11228758
[TBL] [Abstract][Full Text] [Related]
43. Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study.
Hanefeld M; Pfützner A; Forst T; Kleine I; Fuchs W
Cardiovasc Diabetol; 2011 Jul; 10():65. PubMed ID: 21756323
[TBL] [Abstract][Full Text] [Related]
44. Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension.
Jin SM; Park CY; Cho YM; Ku BJ; Ahn CW; Cha BS; Min KW; Sung YA; Baik SH; Lee KW; Yoon KH; Lee MK; Park SW
Diabetes Obes Metab; 2015 Jun; 17(6):599-602. PubMed ID: 25580775
[TBL] [Abstract][Full Text] [Related]
45. Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes.
Roden M; Mariz S; Brazzale AR; Pacini G
J Intern Med; 2009 Apr; 265(4):476-87. PubMed ID: 19298459
[TBL] [Abstract][Full Text] [Related]
46. Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US.
Tolman KG; Freston JW; Kupfer S; Perez A
Drug Saf; 2009; 32(9):787-800. PubMed ID: 19670918
[TBL] [Abstract][Full Text] [Related]
47. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
Bajaj M; Suraamornkul S; Piper P; Hardies LJ; Glass L; Cersosimo E; Pratipanawatr T; Miyazaki Y; DeFronzo RA
J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
[TBL] [Abstract][Full Text] [Related]
48. Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance.
Celik O; Acbay O
J Endocrinol Invest; 2012 Nov; 35(10):905-10. PubMed ID: 22522778
[TBL] [Abstract][Full Text] [Related]
49. Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study.
Musholt PB; Schöndorf T; Pfützner A; Hohberg C; Kleine I; Fuchs W; Hehenwarter S; Dikta G; Kerschgens B; Forst T
J Diabetes Sci Technol; 2009 Nov; 3(6):1442-50. PubMed ID: 20144400
[TBL] [Abstract][Full Text] [Related]
50. [Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia].
Gómez-García A; Martínez Torres G; Ortega-Pierres LE; Rodríguez-Ayala E; Alvarez-Aguilar C
Rev Esp Cardiol; 2007 Dec; 60(12):1242-9. PubMed ID: 18082089
[TBL] [Abstract][Full Text] [Related]
51. Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes.
Marena S; Tagliaferro V; Montegrosso G; Pagano A; Scaglione L; Pagano G
Diabete Metab; 1994; 20(1):15-9. PubMed ID: 8056129
[TBL] [Abstract][Full Text] [Related]
52. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.
Samson SL; Sathyanarayana P; Jogi M; Gonzalez EV; Gutierrez A; Krishnamurthy R; Muthupillai R; Chan L; Bajaj M
Diabetologia; 2011 Dec; 54(12):3093-100. PubMed ID: 21956711
[TBL] [Abstract][Full Text] [Related]
53. Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes.
Mori Y; Itoh Y; Obata T; Tajima N
Endocrine; 2006 Feb; 29(1):143-8. PubMed ID: 16622303
[TBL] [Abstract][Full Text] [Related]
54. Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes.
Perez A; Jacks R; Arora V; Spanheimer R
J Clin Hypertens (Greenwich); 2010 Dec; 12(12):973-82. PubMed ID: 21122063
[TBL] [Abstract][Full Text] [Related]
55. Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms.
Fernandez M; Triplitt C; Wajcberg E; Sriwijilkamol AA; Musi N; Cusi K; DeFronzo R; Cersosimo E
Diabetes Care; 2008 Jan; 31(1):121-7. PubMed ID: 17909084
[TBL] [Abstract][Full Text] [Related]
56. Comparison of orlistat treatment and placebo in obese type 2 diabetic patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; D'Angelo A; Fogari E; Palumbo I; Randazzo S; Cicero AF
Expert Opin Pharmacother; 2010 Aug; 11(12):1971-82. PubMed ID: 20569086
[TBL] [Abstract][Full Text] [Related]
57. Tolerability profile of metformin/glibenclamide combination tablets (Glucovance): a new treatment for the management of type 2 diabetes mellitus.
Davidson JA; Scheen AJ; Howlett HC
Drug Saf; 2004; 27(15):1205-16. PubMed ID: 15588116
[TBL] [Abstract][Full Text] [Related]
58. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.
Park JS; Cho MH; Nam JS; Yoo JS; Ahn CW; Cha BS; Kim KR; Lee HC
Eur J Endocrinol; 2011 Jan; 164(1):69-74. PubMed ID: 20961967
[TBL] [Abstract][Full Text] [Related]
59. Effect of troglitazone on body fat distribution in type 2 diabetic patients.
Mori Y; Murakawa Y; Okada K; Horikoshi H; Yokoyama J; Tajima N; Ikeda Y
Diabetes Care; 1999 Jun; 22(6):908-12. PubMed ID: 10372240
[TBL] [Abstract][Full Text] [Related]
60. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.
Gastaldelli A; Harrison SA; Belfort-Aguilar R; Hardies LJ; Balas B; Schenker S; Cusi K
Hepatology; 2009 Oct; 50(4):1087-93. PubMed ID: 19670459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
